



**PURDUE**  
P H A R M A C Y

CENTER FOR MEDICATION  
SAFETY ADVANCEMENT

# Promoting Patient Safety Through Integration of Large Data Sets, Metrics, and Dashboards

Kyle E. Hultgren, PharmD

Director | Center for Medication Safety Advancement

Clinical Assistant Professor of Pharmacy Practice

Purdue University College of Pharmacy

# Objectives

- Summarize various sources that can be used to collect data on medication use
- Design a medication safety dashboard for use in a health system setting
- Describe large data set analysis and how it may be used to improve the medication use process

# Case Study

A 250 bed hospital that has an electronic medical record is looking to understand how safe their medication use process is. The currently utilize ADCs and are bringing smart pumps (intelligent infusion devices) online in the near future. They feel like they have lots of data but are not sure how to interpret it in order to make a determination on safety. How would you instruct them to proceed?

# Where to start?

NCBI Resources ▾ How To ▾ Sign in to NCBI

PubMed.gov  
US National Library of Medicine  
National Institutes of Health

PubMed ▾ medication safety measurement Search

RSS Save search Advanced Help

Show additional filters

Article types  
Clinical Trial  
Review  
More ...

Text availability  
Abstract  
Free full text  
Full text

Publication dates  
5 years  
10 years  
Custom range...

Species  
Humans  
Other Animals

Clear all

Show additional filters

Display Settings: ▾ Summary, 20 per page, Sorted by Recently Added

Send to: ▾ Filters: [Manage Filters](#)

**Results: 1 to 20 of 1252** << First < Prev Page 1 of 63 Next > Last >>

☐ [The morbidity and mortality conference as an adverse event surveillance tool in a paediatric intensive care unit.](#)  
1. Cifra CL, Jones KL, Ascenzi J, Bhalala US, Bembea MM, Fackler JC, Miller MR.  
BMJ Qual Saf. 2014 Jul 18. pii: bmjqs-2014-003000. doi: 10.1136/bmjqs-2014-003000. [Epub ahead of print]  
PMID: 25038037 [PubMed - as supplied by publisher]  
[Related citations](#)

☐ [Comparison of 4% articaine and 0.5% bupivacaine anesthetic efficacy in orthodontic extractions: Prospective, randomized crossover study.](#)  
2. Thakare A, Bhate K, Kathariya R.  
Acta Anaesthesiol Taiwan. 2014 Jun;52(2):59-63. doi: 10.1016/j.aat.2014.04.006. Epub 2014 Jun 11.  
PMID: 25016509 [PubMed - in process]  
[Related citations](#)

☐ [Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand.](#)  
3. Lucas GM, Young A, Donnell D, Richardson P, Aramrattana A, Shao Y, Ruan Y, Liu W, Fu L, Ma J, Celentano DD, Metzger D, Jackson JB, Burns D.  
Drug Alcohol Depend. 2014 Jun 19. pii: S0376-8716(14)00921-1. doi: 10.1016/j.drugalcdep.2014.06.013. [Epub ahead of print]  
PMID: 24999060 [PubMed - as supplied by publisher]  
[Related citations](#)

**New feature**  
Try the new Display Settings option - Sort by Relevance

**Results by year**  
  
Download CSV

**Titles with your search terms**  
Improving medication safety: the measurement conundrum and wh [Int J Qual Health Care. 2003]  
See more...

**121 free full-text articles in PubMed Central**  
Update to the study protocol for a randomized controlled trial comparing mindfulness [Trials. 2014]

# Where to start?

NCBI Resources ▾ How To ▾ Sign in to NCBI

PubMed.gov  
US National Library of Medicine  
National Institutes of Health

PubMed ▾ medication safety measurement Search

RSS Save search Advanced Help

Show additional filters

Display Settings: ▾ Summary, 20 per page, Sorted by Recently Added

Send to: ▾ Filters: Manage Filters

Article types  
Clinical Trial  
Review  
More ...

Text availability  
Abstract  
Free full text  
Full text

Publication dates  
5 years  
10 years  
Custom range...

Species  
Humans  
Other Animals

Clear all

Show additional filters

**Results: 1 to 20 of 1252**

1. [The morbidity and mortality conference as an adverse event surveillance tool in a paediatric intensive care unit.](#)  
Cifra CL, Jones KL, Ascenzi J, Bhalala US, Bembea MM, Fackler JC, Miller  
BMJ Qual Saf. 2014 Jul 18. pii: bmjqs-2014-003000. doi: 10.1136/bmjqs-2014-003000.  
PMID: 25038037 [PubMed - as supplied by publisher]  
[Related citations](#)

2. [Comparison of 4% articaine and 0.5% bupivacaine anesthetic efficacy in orthodontic extractions: Prospective, randomized crossover study.](#)  
Thakare A, Bhate K, Kathariya R.  
Acta Anaesthesiol Taiwan. 2014 Jun;52(2):59-63. doi: 10.1016/j.aat.2014.04.006. Epub 2014 Jun 11.  
PMID: 25016509 [PubMed - in process]  
[Related citations](#)

3. [Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand.](#)  
Lucas GM, Young A, Donnell D, Richardson P, Aramrattana A, Shao Y, Ruan Y, Liu W, Fu L, Ma J, Celentano DD, Metzger D, Jackson JB, Burns D.  
Drug Alcohol Depend. 2014 Jun 19. pii: S0376-8716(14)00921-1. doi: 10.1016/j.drugalcdep.2014.06.013. [Epub ahead of print]  
PMID: 24999060 [PubMed - as supplied by publisher]  
[Related citations](#)

Helpful?

Results by year

Download CSV

Titles with your search terms

Improving medication safety: the measurement conundrum and wh [Int J Qual Health Care. 2003]

See more...

121 free full-text articles in PubMed Central

Update to the study protocol for a randomized controlled trial comparing mindfulness [Trials. 2014]

# Where to start?

NCBI Resources ▾ How To ▾ Sign in to NCBI

PubMed.gov  
US National Library of Medicine  
National Institutes of Health

PubMed ▾ medication safety measurement Search

RSS Save search Advanced Help

Show additional filters

Display Settings: ▾ Summary 20 per page, Sorted by Recently Added

Send to: ▾ Filters: Manage Filters

**Results: 1 to 20 of 1252**

Article types  
Clinical Trial  
Review  
More ...

Text availability  
Abstract  
Free full text  
Full text

Publication dates  
5 years  
10 years  
Custom range...

Species  
Humans  
Other Animals

Clear all

Show additional filters

1. [The morbidity and mortality conference as an adverse event surveillance tool in a paediatric intensive care unit.](#)  
Cifra CL, Jones KL, Ascenzi J, Bhalala US, Bembea MM, Fackler JC, Miller  
BMJ Qual Saf. 2014 Jul 18. pii: bmjqs-2014-003000. doi: 10.1136/bmjqs-2014-003000.  
PMID: 25038037 [PubMed - as supplied by publisher]  
[Related citations](#)

2. [Comparison of 4% articaine and 0.5% bupivacaine anesthetic efficacy in orthodontic extractions: Prospective, randomized crossover study.](#)  
Thakare A, Bhate K, Kathariya R.  
Acta Anaesthesiol Taiwan. 2014 Jun;52(2):59-63. doi: 10.1016/j.aat.2014.04.006. Epub 2014 Jun 11.  
PMID: 25016509 [PubMed - in process]  
[Related citations](#)

3. [Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand.](#)  
Lucas GM, Young A, Donnell D, Richardson P, Aramrattana A, Shao Y, Ruan Y, Liu W, Fu L, Ma J, Celentano DD, Metzger D, Jackson JB, Burns D.  
Drug Alcohol Depend. 2014 Jun 19. pii: S0376-8716(14)00921-1. doi: 10.1016/j.drugalcdep.2014.06.013. [Epub ahead of print]  
PMID: 24999060 [PubMed - as supplied by publisher]  
[Related citations](#)

Helpful?

Results by year

Download CSV

**Titles with your search terms**  
Improving medication safety: the measurement conundrum and wh [Int J Qual Health Care. 2003]  
See more...

**121 free full-text articles in PubMed Central**  
Update to the study protocol for a randomized controlled trial comparing mindfulness [Trials. 2014]

What about this?

# Medication Safety Metrics

*International Journal for Quality in Health Care* 2003; Volume 15, Supplement 1: pp. i41–i47

10.1093/intqhc/mzg083

## Improving medication safety: the measurement conundrum and where to start

DAVID C. CLASSEN<sup>1</sup> AND JANE METZGER

The University of Utah School of Medicine, Salt Lake City, UT, <sup>1</sup>First Consulting Group Lexington, MA, USA

### Abstract

The use of medication remains the most common intervention in health care. The complexity of both medication use and the medication management process, especially in the in-patient setting, create a significant risk for hospitalized patients. Despite the widespread recognition of the hazards that medication use poses to patients, there are no widely accepted or standardized methods to measure the safety of medication use. Where to focus measurement in medication safety is the subject of ongoing debate. Various groups have suggested measuring error-prone aspects of the medication use process such as errors in administration of medications or errors in dispensing of medications. Other groups have suggested measuring adverse drug events as a measure of the safety of medication use. Many studies in this area have outlined the great difficulty associated with getting clinicians to report either medication errors or adverse drug events voluntarily. In response to these challenges, yet more groups have developed non-voluntary reporting methods based on the use of 'triggers', in either a chart review or electronic format. Medication safety is a complex process and measurement of it needs to be a core component throughout the whole process. With the introduction of computerized analysis of patient information, measurement becomes much easier and more

# Medication Safety Metrics

- The purpose and meaning behind measurement
  - Learn and improve
  - Ensure accountability
  - Intervene
- Data to collect (suggestions)
  - Pharmacy
  - Lab
  - Medication administration
  - Prescribing

\*\*\*Takeaway from Classen: Start somewhere with something and make it electronic

# Medication Safety Metrics



## PRACTICE REPORTS

### Systematic review of medication safety assessment methods

CARLA MEYER-MASETTI, CHRISTINE M. CHENG, DAVID L. B. SCHWAPPACH, LYNN PAULSEN, BRIGID IDE, CHRISTOPH R. MEIER, AND B. JOSEPH GUGLIELMO

**T**he health-related and economic burdens associated with drug-related problems (DRPs), including adverse drug events (ADEs), adverse drug reactions (ADRs), and medication errors (MEs), have resulted in requirements to ensure

**Purpose.** The accuracy, efficiency, and efficacy of four commonly recommended medication safety assessment methodologies were systematically reviewed.

**Methods.** Medical literature databases were systematically searched for any comparative study conducted between January

showed a higher specificity compared to the other methods and most effectively captured severe DRPs. In contrast, the sensitivity of incident report review was lower when compared with trigger tool. While trigger tool was the least labor-intensive of the four methodologies, incident report

# Medication Safety Metrics

- A robust picture of medication safety
  - Voluntary reports
  - Automated trigger tool data
  - Direct observation
  - Chart review – electronic or manual
  - Data from technology (Smart Pumps, Automated Dispensing Cabinets, Electronic Medical Records)

\*\*\*Takeaway from Meyer-Masseti: Strengths and weaknesses with various data sources. Multiple data sources necessary to get full picture of medication safety

# Medication Safety Metrics

- Significant focus on definitions
  - Keep this for yourself and stick to it
- Consensus based adoption of definition
  - Sometimes just move on
- Surveillance or Reporting . . . . . or both
- Be open to benchmarking and sharing best practice

# Incident Reports

- Take many different forms
  - Free text
  - Drop down boxes
  - Online
  - Manual
  - Verbal conversations
- Focuses on human recall of an event and includes *perception* of the facts

# A practical look

## PROS

- May include a narrative aspect to tell the “story”
- Firsthand knowledge of the event
- Typically only reported when an event or harm has occurred (if even then – still a dramatic under-reporting rate – see CONS)

## CONS

- Under reporting
- Fear of misuse (blame) in a poor safety culture
- Perceptions may vary based upon who is reporting

# Trigger Tools

## ERRORS & ADVERSE EVENTS

By David C. Classen, Roger Resar, Frances Griffin, Frank Federico, Terri Frankel, Nancy Kimmel, John C. Whittington, Allan Frankel, Andrew Seger, and Brent C. James

### 'Global Trigger Tool' Shows That Adverse Events In Hospitals May Be Ten Times Greater Than Previously Measured

**ABSTRACT** Identification and measurement of adverse medical events is central to patient safety, forming a foundation for accountability, prioritizing problems to work on, generating ideas for safer care, and testing which interventions work. We compared three methods to detect adverse events in hospitalized patients, using the same patient sample set from three leading hospitals. We found that the adverse event detection

**DOI:** 10.1377/hlthaff.2011.0190  
HEALTH AFFAIRS 30,  
NO. 4 (2011): ~  
©2011 Project HOPE—  
The People-to-People Health  
Foundation, Inc.

**David C. Classen** (dclassen@csc.com) is an associate professor of medicine at the University of Utah, in Salt Lake City.

**Roger Resar** is a senior fellow at the Institute for Healthcare Improvement, in Cambridge, Massachusetts.

# IHI Global Trigger Tool

- Looking for “clues” = triggers
- These clues will tip us off to likely adverse events in patient charts
- Retrospective review of patient charts for triggers resulting in harm
- Overall goal is reduction of harm

# Triggers – Medication Module

- M1 – C. Diff positive stool
- M2 – PTT > 100 seconds
- M3 – INR > 6
- M4 – Glucose > 50mg/dL
- M5 – Rising BUN or SCr over 2x baseline
- M6 – vitamin K administration
- M7 – diphenhydramine administration
- M8 – romazicon administration
- M9 – naloxone administration
- M10 – Anti-emetic administration
- M11 – Over-sedation/hypotension
- M12 – Abrupt medication stop
- M13 – Other

# A practical look


## PROS

- Thorough look at full charts
- Repeatable process design
- Helps to identify trends
- Can create objective, quantitative data on safety

## CONS

- Retrospective
- “False positives”
- Sample size, not full representation
- Manual process
- Based on pre-defined triggers, not a full retrospective review

# Direct Observation



# Direct Observation

- Concept developed to study various aspects of medication use process
- Independent, trained observers watch a medication administration take place and document the process with their observations
  - Watches 50 – 100 doses administered
  - Documents findings

# Direct Observation

- Observer's notes get reconciled against the original orders to determine if there are any discrepancies
- Data are then reported and tracked
- Observations can be made quite often if an organization has resources available for it

# A practical look

## PROS

- Actually observing in real time as the administration progresses
- Process-based observations strengthen “ownership” of results
- Helps to identify trends
- Can create objective, quantitative data on safety

## CONS

- Resource intensive
- Potential “Hawthorne effect”
- Only a sampling at one given time
- Manual process

# Device Data

- Identify generally regarded as safe practices



# Device Data

- Bar Code Medication Administration Scan Rates

# of medications scanned prior to administration

---

Total # of medications charted as administered

==

% scan rate

# Be careful not to make assumptions

Patient with an INR of 6.7 walks into clinic for their visit without any signs of bleeding.

VS.

Patient with an INR of 4.1 admitted to ED for uncontrolled bleed associated with minor cut.

# Causality?

- Can be “data rich and information poor”
- Avoid the pitfall of assuming causality exists simply because you have a data point
- False causality
  - Data: 40,000 automobile accidents in 1 year
  - Data: 30,000 vehicles were red
  - Inference: Red vehicles cause more accidents

# Large Data Sets

- Some events happen infrequently in various settings
- Must take advantage of global knowledge in this area
- Population level information on adverse events and reactions can be available through different outlets

# Examples of Data Sources for Patient Safety

- External (National and beyond)
  - Agency for Healthcare Research & Trust (AHRQ)
  - CMS Hospital Compare (Patient Safety Indicators, HCAHPS)
  - MEDMARX Adverse Drug Events
  - NDNQI, MDS (Falls and Pressure Ulcers)
  - The Joint Commission
  - Food & Drug Administration
    - [Open Adverse Event page](#)
  - Patient Safety Organizations
  - International (NHS, Uppsala Monitoring Center)

# Indianapolis Coalition for Patient Safety

## SMART Pump Data Hub

MEDICATION-USE T

### Comparative analytics of infusion pump data across multiple hospital systems

ANN CHRISTINE CATLIN, WILLIAM X. MALLOY, KAREN J. ARTHUR, CINDY GASTON, JAMES YOUNG, SUDHEERA FERNANDO, AND RUCHITH FERNANDO

**M**edication errors are commonly associated with i.v. and high-risk medications that may cause severe patient harm.<sup>1-4</sup> Smart infusion pumps improve the safety of i.v. medication adminis-


**Purpose.** A Web-based analytics system for conducting inhouse evaluations and cross-facility comparisons of alert data generated by smart infusion pumps is described.

**Summary.** The Infusion Pump Informatics (IPI) project, a collaborative effort led by

Indiana hospitals were the first IPI community members and provided alert data generated by their smart-pump systems (Alaris, CareFusion Corporation, San Diego, CA) for upload and secure storage in the IPI database. Medication safety analysts from each institution were then provided full access to investigate alerts and compare data across both

bers of alerts per device or care area, and override-to-alert ratios, (2) investigative reports that can be used to characterize and analyze pump-programming errors in a variety of ways (e.g., by drug, by infusion type, by time of day), and (3) "drill-down"

# Infusion Pump Informatics (IPI)



# How Does IPI Support Patient Safety?

| <div> <div>First Previous 1 2 3 4 5 Next Last</div> <div>Search</div> </div> |           |      |             |            |            |                 |          |            |             |                 |                     |           |              |             |             |               |
|------------------------------------------------------------------------------|-----------|------|-------------|------------|------------|-----------------|----------|------------|-------------|-----------------|---------------------|-----------|--------------|-------------|-------------|---------------|
|                                                                              | Hard/Soft | Type | Above/Below | Drug Limit | Programmed | Amount Exceeded | Units    | % Exceeded | Times Limit | Field Limit     | Date                | Device ID | Action Taken | Drug Amount | Diluent Vol | Concentration |
|                                                                              | Hard/Soft | Type | Above/Below | Limit      | Programmed | Amount Exceeded | Units    | % Exceeded | Times Limit | Field Limit     | Date                | Device ID |              | Drug Amount | Diluent Vol | Concentration |
| tial                                                                         | Soft      | Dose | Above Max   | 20.00      | 160.00     | 140.00          | mcg/kg/h | 700        | 8.00        | Continuous Dose | 08-17-2013 10:58:23 | 12549484  | Override     | 40.000 mg   | 100.00      | 400.000 mcg   |
| tial                                                                         | Soft      | Dose | Above Max   | 20.00      | 160.00     | 140.00          | mcg/kg/h | 700        | 8.00        | Continuous Dose | 08-17-2013 11:50:32 | 12549484  | Reprogram    | 40.000 mg   | 100.00      | 400.000 mcg   |
| tial                                                                         | Soft      | Dose | Above Max   | 20.00      | 160.00     | 140.00          | mcg/kg/h | 700        | 8.00        | Continuous Dose | 08-17-2013 11:56:16 | 12549484  | Override     | 40.000 mg   | 100.00      | 400.000 mcg   |
| tial                                                                         | Soft      | Dose | Above Max   | 20.00      | 160.00     | 140.00          | mcg/kg/h | 700        | 8.00        | Continuous Dose | 08-17-2013 14:24:44 | 12549484  | Override     | 40.000 mg   | 100.00      | 400.000 mcg   |
| tial                                                                         | Soft      | Dose | Above Max   | 20.00      | 160.00     | 140.00          | mcg/kg/h | 700        | 8.00        | Continuous Dose | 08-17-2013 18:10:48 | 12549484  | Override     | 40.000 mg   | 100.00      | 400.000 mcg   |
| tial                                                                         | Soft      | Dose | Above Max   | 20.00      | 160.00     | 140.00          | mcg/kg/h | 700        | 8.00        | Continuous Dose | 08-17-2013 20:00:57 | 12549484  | Override     | 40.000 mg   | 100.00      | 400.000 mcg   |
| tial                                                                         | Soft      | Dose | Above Max   | 20.00      | 160.00     | 140.00          | mcg/kg/h | 700        | 8.00        | Continuous Dose | 08-17-2013 21:18:42 | 12549484  | Override     | 40.000 mg   | 100.00      | 400.000 mcg   |
| tial                                                                         | Soft      | Dose | Above Max   | 20.00      | 160.00     | 140.00          | mcg/kg/h | 700        | 8.00        | Continuous Dose | 08-17-2013 21:55:35 | 12549484  | Override     | 40.000 mg   | 100.00      | 400.000 mcg   |
| tial                                                                         | Soft      | Dose | Above Max   | 20.00      | 160.00     | 140.00          | mcg/kg/h | 700        | 8.00        | Continuous Dose | 08-17-2013 22:35:25 | 12549484  | Override     | 40.000 mg   | 100.00      | 400.000 mcg   |
| tial                                                                         | Soft      | Dose | Above Max   | 20.00      | 160.00     | 140.00          | mcg/kg/h | 700        | 8.00        | Continuous Dose | 08-17-2013 23:13:16 | 12549484  | Override     | 40.000 mg   | 100.00      | 400.000 mcg   |
| tial                                                                         | Soft      | Dose | Above Max   | 20.00      | 160.00     | 140.00          | mcg/kg/h | 700        | 8.00        | Continuous Dose | 08-17-2013 23:54:14 | 12549484  | Override     | 40.000 mg   | 100.00      | 400.000 mcg   |
| tial                                                                         | Soft      | Dose | Above Max   | 20.00      | 160.00     | 140.00          | mcg/kg/h | 700        | 8.00        | Continuous Dose | 08-18-2013 00:33:50 | 12549484  | Override     | 40.000 mg   | 100.00      | 400.000 mcg   |
| tial                                                                         | Soft      | Dose | Above Max   | 20.00      | 160.00     | 140.00          | mcg/kg/h | 700        | 8.00        | Continuous Dose | 08-18-2013 01:18:48 | 12549484  | Override     | 40.000 mg   | 100.00      | 400.000 mcg   |
| tial                                                                         | Soft      | Dose | Above Max   | 20.00      | 160.00     | 140.00          | mcg/kg/h | 700        | 8.00        | Continuous Dose | 08-18-2013 03:53:36 | 12549484  | Override     | 40.000 mg   | 100.00      | 400.000 mcg   |
| tial                                                                         | Soft      | Dose | Above Max   | 20.00      | 160.00     | 140.00          | mcg/kg/h | 700        | 8.00        | Continuous Dose | 08-18-2013 04:31:27 | 12549484  | Override     | 40.000 mg   | 100.00      | 400.000 mcg   |
| tial                                                                         | Soft      | Dose | Above Max   | 20.00      | 160.00     | 140.00          | mcg/kg/h | 700        | 8.00        | Continuous Dose | 08-18-2013 06:55:49 | 12549484  | Override     | 40.000 mg   | 100.00      | 400.000 mcg   |
| tial                                                                         | Soft      | Dose | Above Max   | 20.00      | 160.00     | 140.00          | mcg/kg/h | 700        | 8.00        | Continuous Dose | 08-18-2013 07:33:38 | 12549484  | Override     | 40.000 mg   | 100.00      | 400.000 mcg   |
| tial                                                                         | Soft      | Dose | Above Max   | 20.00      | 160.00     | 140.00          | mcg/kg/h | 700        | 8.00        | Continuous Dose |                     |           |              |             |             | mcg           |
| tial                                                                         | Soft      | Dose | Above Max   | 20.00      | 160.00     | 140.00          | mcg/kg/h | 700        | 8.00        | Continuous Dose |                     |           |              |             |             | mcg           |
| tial                                                                         | Soft      | Dose | Above Max   | 20.00      | 160.00     | 140.00          | mcg/kg/h | 700        | 8.00        | Continuous Dose |                     |           |              |             |             | mcg           |

Showing 1 to 20 of 99 entries

What / where / why / how ?

Every detail from the captured alert data

# How Does IPI Support Patient Safety?

### Investigate


Above Limit by Dose ✖

**Show** 20 ▾ **entries**

First Previous 1 2 3 Next Last

## Search

Ratio: Overrides to Reprograms By Month (Selected Hospitals) : 1st, January 2012 to 31st, December 2012



# Data Repositories

## Questions about data management:

- Who oversees?
- Central vs. decentralized?
- Is there an internal data integrity or validation processes?
- Is data 'locked' after a period of time once validated?
- How to manage qualitative vs. quantitative information

# Developing and Implementing a Safety Dashboard



# Design the Dashboard

- Purpose
  - To communicate to end users
  - Consider sharing with non-end users, survey for potential conflicting messages (pharmacy, nursing, quality/risk, physicians, c-suite, etc.)
- Use simple visual cues
- Include at a minimum
  - Dashboard name
  - Dashboard categories
  - Dashboard measures
  - Dashboard display tool



# VUH Pharmacy Executive Scorecard

| PERFORMANCE INDICATORS           |                                                    |                          | Monthly Goal | JUL | AUG | SEP | OCT |
|----------------------------------|----------------------------------------------------|--------------------------|--------------|-----|-----|-----|-----|
| PEOPLE                           |                                                    |                          |              |     |     |     |     |
| Retention (previous 18 months)   | Inpatient                                          | 65%                      |              |     |     |     |     |
|                                  | Clinic                                             | 65%                      |              |     |     |     |     |
|                                  | Retail                                             | 65%                      |              |     |     |     |     |
| SERVICE                          |                                                    |                          |              |     |     |     |     |
| ADC Stockouts                    | Inpatient                                          | <1.5% total refill lines |              |     |     |     |     |
|                                  | Clinic                                             | <1.5% total refill lines |              |     |     |     |     |
| Order Processing Time:           | Inpatient = CPOE Order Processing Time for STAT    | 90% in < 10 min          |              |     |     |     |     |
|                                  | Inpatient = CPOE Order Processing Time for NOW     | 90% in < 15 min          |              |     |     |     |     |
|                                  | Inpatient = CPOE Order Processing Time for ROUTINE | 90% in < 30 min          |              |     |     |     |     |
| QUALITY AND SAFETY               |                                                    |                          |              |     |     |     |     |
| ADC Overrides                    | Inpatient                                          | <5%                      |              |     |     |     |     |
| Bio ID Utilization with AcuDose  | Inpatient                                          | 90%                      |              |     |     |     |     |
|                                  | Clinic                                             | 90%                      |              |     |     |     |     |
| BIO ID Success Rate With AcuDose | Inpatient                                          | 90%                      |              |     |     |     |     |
|                                  | Clinic                                             | 90%                      |              |     |     |     |     |
| GROWTH                           |                                                    |                          |              |     |     |     |     |
| Pharmacy Items                   | Inpatient                                          | VARIABLES                |              |     |     |     |     |
|                                  | Clinic                                             | VARIABLES                |              |     |     |     |     |
|                                  | Retail                                             | VARIABLES                |              |     |     |     |     |
| Orders Processed                 | Inpatient (includes VPH)                           | TBD                      |              |     |     |     |     |
|                                  | Clinic                                             | TBD                      |              |     |     |     |     |
|                                  | 100 Oaks                                           | TBD                      |              |     |     |     |     |
|                                  | Retail                                             | TBD                      |              |     |     |     |     |

# Remember to...Make it Visible!

- Make the measures everyone's responsibility
  - Encourage accountability
- Post publicly reported data
- Reward and share successes
  - Communicate feedback often
  - Present at regularly scheduled intervals
- Work together to overcome challenges
- Review dashboards and scorecards at least annually



# Questions?

Kyle E. Hultgren, PharmD  
[khultgre@purdue.edu](mailto:khultgre@purdue.edu)